V-Wave’s minimally-invasive implanted interatrial shunt device for treating patients with severe symptomatic heart failure (HF) is designed to regulate Left Atrial Pressure (LAP), the primary cause of breathing difficulty and hospitalization due to worsening HF.
V-Wave develops percutaneous implantable therapeutic devices for chronic Heart Failure (HF) patients. Based in Israel and Los Angeles, our team has a track record of multiple successes in early-stage medical device companies.
Uniquely Designed for Safe and Effective LAP RegulationThe V-Wave Shunt is a miniature, biocompatible interatrial implant, providing a novel therapeutic approach for patients with chronic HF.
The shunt is designed to regulate LAP, the cause of worsening symptoms that lead to over 3 million hospitalizations a year. It is intended to prevent episodes of elevated LAP and is thus expected to provide symptom relief, decrease hospitalization, increase exercise tolerance, improve quality of life and perhaps even extend survival.
Clinical investigation of the V-Wave shunt has begun in North America, Europe and Israel. For more information about our current heart failure clinical research study, please visit: https://www.heartfailureclinicaltrial.com/
Information regarding the trial is also available at ClinicalTrials.gov: https://clinicaltrials.gov/ct2/show/NCT03499236
CAUTION: The V-Wave Interatrial Shunt System is under Clinical Investigation in the United States and other countries (not approved for commercial sale / use).
V-Wave Ltd. is a privately held company with offices in Israel and the US. The company is focused on developing percutaneous implantable devices for treating patients with chronic Heart Failure (HF).
As a leading cause of death and hospitalization, HF continues to affect millions of people worldwide. V-Wave’s vision is to help patients who remain with disabling symptoms or need hospitalization despite optimized medical treatment.
V-Wave has developed a proprietary interatrial shunt intended to relieve symptoms, reduce hospitalization, increase exercise capacity and improve the overall quality of life.
The original concept and development started in Israel with a talented team of engineers and medical scientists. The company’s senior management has decades of experience successfully developing, clinically testing and bringing to market multiple implantable cardiovascular devices.
Originally trained in systems engineering at UCLA, Dr. Neal Eigler attended Yale Medical School and was a Cardiovascular Fellow at Cedars-Sinai Hospital. Alongside Dr. Frank Litvack, he served as Co-Director of Cardiac Intervention at Cedars-Sinai for more than two decades, holding the academic rank of Professor of Medicine at UCLA.
Dr. Eigler has 44 issued U.S. patents for medical devices. He was a Co-Founder and/or Medical Director of Progressive Angioplasty System (PAS) and Conor MedSystems, where he co-invented the multi-drug delivery stent platform with programmable elution kinetics. In 2000, Dr. Eigler founded and served as CEO at Savacor, a developer of an implantable left atrial pressure sensing system that was linked to a real-time patient self-management system for treating heart failure. After the acquisition of the company, he remained with St. Jude (acquiring company) as a Senior Vice President of Technology Incubation from 2006 through 2014.
Since joining V-Wave as CEO in early 2015, he has assembled a first-rate senior management team, overseen the evolution of the company’s shunt products and clinical indications, including demonstration of clinical proof-of-principle and regulatory approval for a pivotal trial, and successfully concluded B and C round private equity financings.
Mr. Rozenfeld has a proven track record in successful initiation and execution of high-return global business development plans in the field of medical devices. He has implemented new business models and strategic plans, overseen mergers and acquisitions, and helped medical innovation companies engage new markets, globally.
Mr. Rozenfeld served as Managing Director at Lumenis UK ,as well as in key managerial positions for publicly traded companies, including Teva Group and Agis.
Furthermore, Mr. Rozenfeld has vast experience managing emerging companies as Senior VP global operations at Aesthera Inc., CEO of RapiX and as CEO of V-Wave prior to global expansion.
Mr. Rozenfeld holds an Executive MBA and BA from Bar Ilan University, Israel.
Prof. Abraham is director of the Division of Cardiovascular Medicine and a professor of internal medicine, physiology and cell biology at The Ohio State University Wexner Medical Center.
He also serves as Associate Director for Clinical and Translational Research at the Dorothy M. Davis Heart and Lung Research Institute.
Prof. Abraham is an internationally known researcher in heart failure. His research interests include hemodynamic and neurohormonal mechanisms in heart failure, sleep disordered breathing in heart failure, and clinical drug and device trials in heart failure and cardiac transplantation.
Prof. Abraham has participated as a site principal investigator in more than 100 multicenter clinical drug and device trials. He has also served as national or international principal investigator and on the steering committees of more than 30 multicenter clinical drug and device trials.
Dr. Litvack received his MD from McGill University and was trained in Cardiology at Cedars-Sinai Hospital. From 1986-2000 he was Co-Director of the Cardiovascular Intervention Center. He was Professor of Medicine at UCLA School of Medicine. Dr. Litvack has co-founded, operated and served as Chairman of a number of innovative companies including:
– Chairman of Progressive Angioplasty System (PAS), the developer of the stent delivery system for the original Palmaz-Schatz stent and other products. PAS was acquired by U.S. Surgical in 1997.
– CEO and Chairman of Conor MedSystems, a developer of innovative drug eluting stent technology. Dr Litvack took Conor public in 2004 and it was later acquired by Johnson & Johnson in 2007.
– Chairman of Savacor, a left atrial pressure monitoring company that was acquired by St. Jude Medical in 2005.
Dr. Litvack currently serves on several corporate Boards and is a Founding Partner of Pura Vida Funds LLC, a healthcare investment firm.
Originally trained in systems engineering at UCLA, Dr. Neal Eigler attended Yale Medical School and was a Cardiovascular Fellow at Cedars-Sinai Hospital. Alongside Dr. Frank Litvack, he served as Co-Director of Cardiac Intervention at Cedars-Sinai for more than two decades, holding the academic rank of Professor of Medicine at UCLA.
Dr. Eigler has 44 issued U.S. patents for medical devices. He was a Co-Founder and/or Medical Director of Progressive Angioplasty System (PAS) and Conor MedSystems, where he co-invented the multi-drug delivery stent platform with programmable elution kinetics. In 2000, Dr. Eigler founded and served as CEO at Savacor, a developer of an implantable left atrial pressure sensing system that was linked to a real-time patient self-management system for treating heart failure. After the acquisition of the company, he remained with St. Jude (acquiring company) as a Senior Vice President of Technology Incubation from 2006 through 2014.
Since joining V-Wave as CEO in early 2015, he has assembled a first-rate senior management team, overseen the evolution of the company’s shunt products and clinical indications, including demonstration of clinical proof-of-principle and regulatory approval for a pivotal trial, and successfully concluded B and C round private equity financings.
Mr. Maor, Partner at BRM, is responsible for life science investments in the firm. He has an extensive background in healthcare as a senior executive with over 22 years experience in the medical device business.
Mr. Maor is currently the Chairman of StrarletDerma and Perfaction.
Dr. ElBardissi is a Principal at Deerfield Management focusing on early to late venture investments in medical technology. Prior to joining Deerfield, he was a Principal at Longitude Capital and served as an Associate in JP Morgan’s Healthcare Investment Banking practice.
Dr. ElBardissi completed his residency training in General Surgery at Brigham and Women’s Hospital and in Cardiothoracic Surgery at Stanford University. He received an MD from the Mayo Clinic, an MPH from Harvard University, and an MBA from Harvard Business School.
Dr. Shmulewitz has more than twenty years of experience as a physician, scientist, inventor, founder, and executive with a positive track record in the US, Europe, and Israel.
Dr. Shmulewitz graduated medical school cum laude from the Technion and holds a Ph.D. in Engineering from Tel-Aviv University.
Dr. Essinger, Operating Partner at Endeavour since 2017, has more than 30 years of entrepreneurial experience in medical devices ranging from product design, clinical and regulatory validation, scale-up and commercial growth, financing, IPO and trade-sale.
Dr. Essinger was CEO of Symetis SA (acquired by Boston Scientific in March 2017) which he grew from concept to an established global market player in the field of Transcatheter Aortic Valve Implant (TAVI). Previously, he was CEO of Isotis (IPO in 2000, acquired by Integra Lifescience in 2007) and founded Symbios Orthopedie SA. Jacques has a MSc in physics and a PhD in biomechanics from the EPFL (Lausanne).
Ms. Es Sabar is CEO & Partner at Quark Venture Inc, which has established one of the largest global health sciences venture funds in partnership with GF Securities, a leading investment bank in China. Ms. Es Sabar is a highly-recognized Canadian life sciences leader and she has served as President & CEO for The Centre for Drug Research and Development, Canada’s national drug development and commercialization center; Head of Marketing and Business Development at Pasteur Merieux Connaught [Sanofi Pasteur], and COO for Medsurge Medical Inc.
Ms. Es Sabar holds an Executive Certificate in Management and Leadership from the MIT Sloan School of Management, a MSc degree in Neurochemistry from the University of London, and a BSc Biochemistry/Chemistry from the University of Salford.
Dr. Fitzgerald is Professor Emeritus and Director of the Center for Cardiovascular Technology at Stanford University Medical and Co-founder / Managing Partner at Triventures where he heads the US office.
Dr. Fitzgerald is an Interventional Cardiologist and has a PhD in Engineering. He has led or participated in over 150 clinical trials and has published over 450 manuscripts/chapters. Dr. Fitzgerald has been principle/founder of 18 healthcare companies in Silicon Valley, has transitioned 13 of these start-ups to medium/large-cap life science companies and remains on several of their advisory boards. He has been a consultant for the FDA for the past 15 years focused on medical technology and more recently, digital health.
Mr. Kariv is Co-founder and Chief Executive Officer of Pontifax, a group of Israeli-based life sciences venture funds focusing on investments in bio-pharmaceutical and med-tech technologies.
Mr. Kariv has also served as an active board member of many of the funds’ portfolio companies, assuming a special responsibility for strategic planning.
Mr. Kariv practiced law with Sullivan & Cromwell, a leading corporate law firm in New York, and holds a B.A. degree in Economics from Harvard University and a J.D. from Harvard Law School.
